

# Clara Natoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1098345/publications.pdf>

Version: 2024-02-01

161  
papers

4,824  
citations

117619

34  
h-index

138468

58  
g-index

164  
all docs

164  
docs citations

164  
times ranked

6740  
citing authors

#	ARTICLE	IF	CITATIONS
1	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends in Immunology, 2002, 23, 313-320.	6.8	493
2	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
3	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. International Journal of Cancer, 2000, 85, 545-554.	5.1	194
4	90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconjugate Journal, 2002, 19, 551-556.	2.7	148
5	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget, 2016, 7, 19738-19747.	1.8	134
6	Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Letters, 2000, 473, 311-315.	2.8	131
7	Prognostic value of a novel circulating serum 90K antigen in breast cancer. British Journal of Cancer, 1994, 69, 172-176.	6.4	123
8	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast, 2019, 44, 33-38.	2.2	109
9	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to Î±-interferon therapy in chronic HCV hepatitis patients. Journal of Hepatology, 1996, 25, 212-217.	3.7	88
10	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
11	Triple positive breast cancer: A distinct subtype?. Cancer Treatment Reviews, 2015, 41, 69-76.	7.7	83
12	GYNÄ†COMASTIA WITH CIMETIDINE. Lancet, The, 1977, 309, 1319.	13.7	80
13	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Review of Vaccines, 2016, 15, 1327-1336.	4.4	79
14	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62.	6.4	68
15	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. Journal of Molecular Medicine, 2013, 91, 83-94.	3.9	63
16	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	10.7	59
17	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Oncotarget, 2015, 6, 35589-35601.	1.8	57
18	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 2017, 8, 56921-56931.	1.8	53

#	ARTICLE	IF	CITATIONS
19	Hormone-modulated rRNA gene activity is visualized by selective staining of the NOs. <i>Cell Biology International Reports</i> , 1985, 9, 791-796.	0.6	52
20	Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. <i>Breast Cancer Research and Treatment</i> , 1988, 11, 19-30.	2.5	52
21	Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. <i>FEBS Letters</i> , 1993, 319, 59-65.	2.8	46
22	Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. <i>Cancer Letters</i> , 2008, 270, 229-233.	7.2	44
23	Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. <i>Anticancer Research</i> , 2009, 29, 403-10.	1.1	43
24	Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3850-3856.	1.6	42
25	Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. <i>Breast Cancer Research and Treatment</i> , 1983, 3, 23-32.	2.5	40
26	90K (Mac-2 BP) in human milk. <i>Clinical and Experimental Immunology</i> , 1996, 104, 543-546.	2.6	40
27	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000, 96, 3282-3285.	1.4	39
28	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
29	Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. <i>Cancer</i> , 2018, 124, 2923-2930.	4.1	39
30	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 236.	8.6	38
31	Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIA study. <i>Immunotherapy</i> , 2018, 10, 1229-1239.	2.0	38
32	Tyrosine Kinase Inhibitors. <i>Current Cancer Drug Targets</i> , 2010, 10, 462-483.	1.6	37
33	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. <i>Cancers</i> , 2013, 5, 919-942.	3.7	37
34	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	37
35	Recombinant human leukocyte interferon- $\gamma$ 2b stimulates the synthesis and release of a 90k tumor-associated antigen in human breast cancer cells. <i>International Journal of Cancer</i> , 1988, 42, 182-184.	5.1	36
36	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. <i>International Journal of Cancer</i> , 2009, 124, 333-338.	5.1	36

#	ARTICLE	IF	CITATIONS
37	Human milk 90K (Mac-2â€fBP): possible protective effects against acute respiratory infections. <i>Clinical and Experimental Immunology</i> , 1999, 115, 91-94.	2.6	35
38	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	1.8	35
39	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. , 1996, 68, 34-38.		34
40	DNA and S-phase fraction analysis by flow cytometry in prostate cancer. <i>Clinicopathologic implications</i> . <i>Cancer</i> , 1993, 71, 1289-1296.	4.1	33
41	Neoadjuvant chemotherapy in tripleâ€negative breast cancer: A multicentric retrospective observational study in realâ€life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	4.1	33
42	â€Triple positiveâ€early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	1.8	33
43	Interleukin-30 Promotes Breast Cancer Growth and Progression. <i>Cancer Research</i> , 2016, 76, 6218-6229.	0.9	32
44	Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	1.3	32
45	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	8.6	32
46	A 90-kDa Protein Serum Marker for the Prediction of Progression to AIDS in a Cohort of HIV-1+Homosexual Men. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 811-816.	1.1	31
47	The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 20-32.	4.4	31
48	Glucocorticoids inhibit the stimulatory effect of epidermal growth factor on the initiation of DNA synthesis. <i>Journal of Cellular Physiology</i> , 1981, 107, 155-163.	4.1	30
49	Unusually High Level of a Tumor-Associated Antigen in the Serum of Human Immunodeficiency Virus-Seropositive Individuals. <i>Journal of Infectious Diseases</i> , 1991, 164, 616-617.	4.0	30
50	Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 62-81.	7.4	30
51	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 221-229.	2.5	30
52	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	4.6	30
53	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	3.4	30
54	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015, 6, 31604-31612.	1.8	30

#	ARTICLE	IF	CITATIONS
55	90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. , 1998, 79, 23-26.		29
56	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. Journal of Pathology, 2002, 197, 218-223.	4.5	29
57	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. Current Cancer Drug Targets, 2012, 12, 439-452.	1.6	29
58	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey. Clinical Breast Cancer, 2015, 15, e131-e137.	2.4	27
59	Estrogen binding by neoplastic human thymus cytosol. European Journal of Cancer, 1980, 16, 951-955.	0.9	26
60	Lipoprotein 90K in Human Immunodeficiency Virus-Infected Patients: A Further Serologic Marker of Progression. Journal of Infectious Diseases, 1991, 164, 819-819.	4.0	26
61	The Immune Stimulatory Protein 90K Increases Major Histocompatibility Complex Class I Expression in a Human Breast Cancer Cell Line. Biochemical and Biophysical Research Communications, 1996, 225, 617-620.	2.1	26
62	Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. British Journal of Cancer, 1993, 67, 564-567.	6.4	25
63	Changes of Topoisomerase III $\pm$ Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. Clinical Cancer Research, 2006, 12, 1501-1506.	7.0	24
64	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. Journal of Experimental and Clinical Cancer Research, 2016, 35, 62.	8.6	24
65	Safety and efficacy of abiraterone acetate in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: an Italian multicenter real life study. BMC Cancer, 2017, 17, 753.	2.6	24
66	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. Journal of Cancer, 2019, 10, 5926-5934.	2.5	24
67	“Back to a false normality” new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	1.8	24
68	Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. International Journal of Cancer, 1994, 59, 808-813.	5.1	23
69	Unknown primary tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 13-24.	7.4	23
70	Tumor-derived microvesicles: The metastasomes. Medical Hypotheses, 2013, 80, 75-82.	1.5	21
71	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti-“Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. Molecular Cancer Therapeutics, 2014, 13, 916-925.	4.1	21
72	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. Journal of Cellular Physiology, 2019, 234, 7708-7717.	4.1	21

#	ARTICLE	IF	CITATIONS
73	Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. <i>British Journal of Haematology</i> , 1993, 85, 207-209.	2.5	20
74	Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. <i>Clinical and Experimental Immunology</i> , 1998, 113, 394-400.	2.6	20
75	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 269-280.	2.5	19
76	Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3007-3015.	2.0	19
77	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	4.1	19
78	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. <i>Clinical Colorectal Cancer</i> , 2012, 11, 229-237.	2.3	18
79	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 125-133.	2.1	18
80	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016, 11, e0157751.	2.5	17
81	The 90K Tumor-Associated Antigen and Clinical Progression in Human Immunodeficiency Virus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 450-456.	0.3	16
82	Expression of the 90K Tumor-Associated Protein in Benign and Malignant Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2002, 119, 187-190.	0.7	16
83	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. <i>Breast</i> , 2016, 29, 96-101.	2.2	16
84	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	3.3	16
85	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	4.1	16
86	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	2.5	16
87	Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 21259-21271.	1.8	16
88	Tamoxifen induced membrane alterations in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , 1984, 20, 425-428.	1.1	15
89	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , 2018, 10, 643-655.	2.0	15
90	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , 2021, 10, 1685.	4.1	15

#	ARTICLE	IF	CITATIONS
91	90K IS A SERUM MARKER OF POOR-PROGNOSIS IN NON-HODGKINS-LYMPHOMA PATIENTS. <i>Oncology Reports</i> , 1994, 1, 723-5.	2.6	15
92	Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1013-1019.	2.3	14
93	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	1.8	14
94	Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. <i>Cancer Letters</i> , 1996, 107, 143-148.	7.2	13
95	Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells. <i>The Journal of Steroid Biochemistry</i> , 1984, 20, 747-752.	1.1	12
96	A Phase I Study of Recombinant Interferon- $\beta$ Administered as a Seven-Day Continuous Venous Infusion at Circadian-Rhythm Modulated Rate in Patients with Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 27-31.	1.3	12
97	A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1015-1020.	1.2	12
98	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. <i>The DECT Trial. Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	4.1	12
99	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	4.1	12
100	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <i>Breast</i> , 2017, 32, 79-86.	2.2	12
101	Body mass index modifies the relationship between $\gamma$ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	2.6	12
102	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	3.4	12
103	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real world setting. <i>Oncotarget</i> , 2017, 8, 69025-69037.	1.8	12
104	Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: A retrospective, observational, multicentric study. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 246-253.	0.9	11
105	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1575-1582.	1.5	11
106	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naïve Patients: An Italian Analysis of Patients' Satisfaction. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 520-525.	1.9	11
107	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
108	Expression of tumor-associated 90k-antigen in human breast cancer: No correlation with prognosis and response to first-line therapy with tamoxifen. <i>International Journal of Cancer</i> , 1995, 64, 130-134.	5.1	10

#	ARTICLE	IF	CITATIONS
109	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017, 8, 54528-54536.	1.8	10
110	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. <i>International Journal of Cancer</i> , 2000, 85, 545.	5.1	10
111	Cyclooxygenase-independent induction of p21WAF-1/cip1, apoptosis and differentiation by L-745,337, a selective PGH synthase-2 inhibitor, and salicylate in HT-29 cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1999, 4, 151-162.	4.9	9
112	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373.	2.5	9
113	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <i>Oncotarget</i> , 2016, 7, 35803-35812.	1.8	9
114	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , 2020, 12, 59-67.	2.0	9
115	Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. <i>Cancer</i> , 1990, 65, 1325-1328.	4.1	8
116	Prognostic Value of a Novel Interferon-inducible 90K Tumor Antigen. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 288-293.	3.8	8
117	Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. <i>Journal of Clinical Immunology</i> , 1999, 19, 143-147.	3.8	8
118	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	2.5	8
119	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 89.	8.6	8
120	Breast Cancer "Tailored Follow-up" in Italian Oncology Units: A Web-Based Survey. <i>PLoS ONE</i> , 2014, 9, e94063.	2.5	8
121	Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 181-184.	3.9	8
122	Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. <i>Aids</i> , 2000, 14, F41-F45.	2.2	7
123	Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?. <i>Cancer Biology and Therapy</i> , 2015, 16, 1704-1709.	3.4	7
124	Rivaroxaban for Cancer-associated Cardiac Thrombosis. <i>American Journal of Medicine</i> , 2015, 128, e43-e44.	1.5	7
125	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. <i>Minerva Urology and Nephrology</i> , 2021, 73, 489-497.	2.5	7
126	Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus. <i>Journal of Infection</i> , 1994, 28, 31-39.	3.3	6



#	ARTICLE	IF	CITATIONS
127	Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer. <i>Disease Markers</i> , 2013, 35, 747-752.	1.3	6
128	Multicentric retrospective analysis of platinum+epemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A snapshot from clinical practice. <i>Thoracic Cancer</i> , 2018, 9, 241-252.	1.9	6
129	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	3.2	6
130	Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: Evidence for differential mechanism of action on tumor cells in vitro. <i>Breast Cancer Research and Treatment</i> , 1985, 6, 255-256.	2.5	5
131	Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. <i>British Journal of Cancer</i> , 1992, 66, 981-983.	6.4	5
132	Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review. <i>Journal of Cancer</i> , 2015, 6, 575-582.	2.5	5
133	Predictive Ability for Disease-Free Survival of the GGrade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. <i>Current Urology</i> , 2020, 14, 98-104.	0.6	5
134	A multidisciplinary group for prostate cancer management: A single institution experience. <i>Oncology Letters</i> , 2017, 15, 1823-1828.	1.8	4
135	A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.3	4
136	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
137	Cyclooxygenase-Independent Induction of P21WAF-1/CIP1, Apoptosis and Differentiation by L-745, 337 and Salicylate in HT-29 Colon Cancer Cells. <i>Advances in Experimental Medicine and Biology</i> , 1999, 469, 555-561.	1.6	4
138	Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents. <i>Anticancer Research</i> , 2018, 38, 3105-3110.	1.1	4
139	Growth inhibitory effects of thyroid hormones on androgen-dependent mammary tumor cells. <i>The Journal of Steroid Biochemistry</i> , 1981, 15, 409-413.	1.1	3
140	Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. <i>British Journal of Cancer</i> , 2004, 91, 618-620.	6.4	3
141	DNA ploidy and S-phase fraction in pulmonary carcinoids. <i>European Journal of Cancer</i> , 1992, 28, 1933-1934.	2.8	2
142	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. <i>Journal of Human Genetics</i> , 2017, 62, 379-387.	2.3	2
143	Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report. <i>International Medical Case Reports Journal</i> , 2017, Volume 10, 173-175.	0.8	2
144	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	2

#	ARTICLE	IF	CITATIONS
145	Tgf- $\beta$ 1 transcriptionally promotes 90K expression: possible implications for cancer progression. Cell Death Discovery, 2021, 7, 86.	4.7	2
146	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood, 2000, 96, 3282-3285.	1.4	2
147	Effect of thyroid hormones on androgen responsiveness in a mammary tumor cell line. The Journal of Steroid Biochemistry, 1981, 15, 415-419.	1.1	1
148	&lt;p&gt;Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib&lt;/p&gt;. International Medical Case Reports Journal, 2020, Volume 13, 89-93.	0.8	1
149	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. Tumori, 2014, 100, e309-13.	1.1	1
150	Combinations of biological response modifiers: rationale and clinical responses.. Pharmacological Research, 1992, 26, 102-103.	7.1	0
151	Chemotherapy-Induced Nausea and Vomiting in Italian Cancer Centers: Results of CINVDAY, a Prospective, Multicenter Study. Tumori, 2014, 100, e309-e313.	1.1	0
152	Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Annals of Oncology, 2015, 26, vi13.	1.2	0
153	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. Breast, 2017, 35, 218-219.	2.2	0
154	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. Breast, 2017, 36, S51-S52.	2.2	0
155	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2-ve Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care, 2020, 15, 30-37.	1.4	0
156	New Targets for Therapy in Pancreatic Cancer. , 0, , .		0
157	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) $\geq$ 75 years (y) old in clinical practice: A multicenter analysis.. Journal of Clinical Oncology, 2014, 32, e14514-e14514.	1.6	0
158	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		0
159	Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A retrospective multicenter observational study.. Journal of Clinical Oncology, 2015, 33, e11542-e11542.	1.6	0
160	CAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21009-e21009.	1.6	0
161	Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. Recenti Progressi in Medicina, 2020, 111, 761-768.	0.8	0